Next Article in Journal
Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins
Next Article in Special Issue
Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines
Previous Article in Journal
Antibody and Cell-Mediated Immune Responses Are Correlates of Protection against Influenza Infection in Vaccinated Older Adults
Previous Article in Special Issue
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase
Review

The Next Generation of Influenza Vaccines: Towards a Universal Solution

1
School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia
2
The Australian Institute for Biotechnology and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia
3
The Australian Infectious Disease Research Centre, The University of Queensland, St Lucia, QLD 4072, Australia
*
Authors to whom correspondence should be addressed.
Vaccines 2021, 9(1), 26; https://doi.org/10.3390/vaccines9010026
Received: 24 December 2020 / Revised: 5 January 2021 / Accepted: 5 January 2021 / Published: 7 January 2021
Influenza viruses remain a constant burden in humans, causing millions of infections and hundreds of thousands of deaths each year. Current influenza virus vaccine modalities primarily induce antibodies directed towards the highly variable head domain of the hemagglutinin protein on the virus surface. Such antibodies are often strain-specific, meaning limited cross-protection against divergent influenza viruses is induced, resulting in poor vaccine efficacy. To attempt to counteract this, yearly influenza vaccination with updated formulations containing antigens from more recently circulating viruses is required. This is an expensive and time-consuming exercise, and the constant arms race between host immunity and virus evolution presents an ongoing challenge for effective vaccine development. Furthermore, there exists the constant pandemic threat of highly pathogenic avian influenza viruses with high fatality rates (~30–50%) or the emergence of new, pathogenic reassortants. Current vaccines would likely offer little to no protection from such viruses in the event of an epidemic or pandemic. This highlights the urgent need for improved influenza virus vaccines capable of providing long-lasting, robust protection from both seasonal influenza virus infections as well as potential pandemic threats. In this narrative review, we examine the next generation of influenza virus vaccines for human use and the steps being taken to achieve universal protection. View Full-Text
Keywords: influenza; vaccine; universal influenza vaccine; hemagglutinin; pandemic influenza; vaccine; universal influenza vaccine; hemagglutinin; pandemic
Show Figures

Figure 1

MDPI and ACS Style

McMillan, C.L.D.; Young, P.R.; Watterson, D.; Chappell, K.J. The Next Generation of Influenza Vaccines: Towards a Universal Solution. Vaccines 2021, 9, 26. https://doi.org/10.3390/vaccines9010026

AMA Style

McMillan CLD, Young PR, Watterson D, Chappell KJ. The Next Generation of Influenza Vaccines: Towards a Universal Solution. Vaccines. 2021; 9(1):26. https://doi.org/10.3390/vaccines9010026

Chicago/Turabian Style

McMillan, Christopher L.D., Paul R. Young, Daniel Watterson, and Keith J. Chappell 2021. "The Next Generation of Influenza Vaccines: Towards a Universal Solution" Vaccines 9, no. 1: 26. https://doi.org/10.3390/vaccines9010026

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop